Universita Degli Studi Di Brescia
- Address
- lock Available on a paid plan
Oncology and Dermatologic Cancer Research
At Universita Degli Studi Di Brescia, clinical research in neoplasms focuses on skin cancer and related precancerous conditions, especially actinic keratosis and cutaneous squamous cell carcinoma. These studies are designed to assess how well treatments can reduce cancer risk, improve disease control, and support better long-term outcomes for patients.
- Evaluating treatment effectiveness in actinic keratosis and preventing progression to invasive disease
- Studying adjuvant therapy strategies for high-risk cutaneous squamous cell carcinoma
- Assessing whether new approaches can improve disease-free survival after standard cancer care
This work reflects a strong interest in both early skin lesion management and more advanced cancer treatment, with the goal of improving outcomes in dermatologic oncology.
Respiratory Medicine and Critical Care Studies
Research in respiratory tract diseases at the Divisione di Pediatria includes studies of acute respiratory distress syndrome, a serious condition that can affect breathing and recovery in critically ill patients. The trials aim to explore new ways to reduce complications and improve survival-related outcomes.
- Testing therapies intended to improve lung recovery in acute respiratory distress syndrome
- Measuring whether treatment can increase time free from mechanical ventilation
- Exploring options that may help prevent longer-term respiratory damage
These studies are centered on better supportive care and treatment effectiveness for patients facing severe respiratory illness.
Immune System and Rare Disease Investigations
The site also supports research into immune system processes and rare inherited conditions such as WHIM syndrome. This area of work focuses on strengthening immune function, reducing infections, and understanding whether targeted treatment can offer lasting benefit for people with complex immune disorders.
- Examining treatments that may raise circulating neutrophil levels in WHIM syndrome
- Assessing long-term safety and tolerability in a rare immune condition
- Supporting better control of infections and immune-related symptoms
These trials highlight a translational approach to rare disease care, combining symptom improvement with broader immune support.
Mixed Therapeutic Research Across Pediatric and Clinical Care
Across its clinical trial portfolio, Universita Degli Studi Di Brescia is contributing to research that spans oncology, respiratory disease, skin disorders, and immunology. The studies are broadly aimed at testing new therapies, comparing treatment options, and improving how clinicians manage both common and rare diseases.
- Comparing active treatment with placebo or standard care to clarify benefit
- Investigating whether new interventions can improve patient outcomes and safety
- Supporting evidence-based care for both chronic and severe conditions
With 7 trials and a large investigator network, the site shows an active commitment to advancing clinical research in multiple therapeutic areas.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 24 therapeutic areas and 15 of 650 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 590 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 130 by active trials.
- 1Novartis Pharma AG10active
lock +129 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG26trials
lock +78 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universita Degli Studi Di Brescia
lock Showing 1 of 518 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21197) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of any body region (except CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 650 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 32 | Unknown | 2014-05-15 | 2026-07-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
